Advertisement

The Contributions of Pathology to the Diagnosis and Management of GVHD: Caveats and Lessons Learned

  • Howard M. ShulmanEmail author
Chapter

Abstract

Pathology plays a significant role in the interpretation of surgical biopsies that provide a clinical diagnosis and aid in the management decisions. By evaluating a collection of biopsies, pathology has helped define the natural history of various manifestations of graft-versus-host disease (GVHD). GVHD affects several organs, most commonly the skin, liver, and gastrointestinal tract. Interpretation of these cases requires knowledge and consideration of GVHD's progression over time and the effects of therapeutic intervention on the respective histology. Pathology is required to distinguish infection and other differential diagnoses from GVHD and to differentiate static changes from active changes. The contemporary diagnostic criterion and recommended format for reporting the organs involved with acute and chronic GVHD are presented.

Keywords

Pathology of GVHD Chronic GVHD Minimal diagnostic criteria for GVHD Sampling of tissues for GVHD NIH consensus panel criteria for diagnosis of chronic GVHD Format for reporting surgical biopsies for GVHD 

References

  1. 1.
    Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report. Biol Blood Marrow Transplant. 2006;12(1):31–47.CrossRefGoogle Scholar
  2. 2.
    Shulman HM, Cardona DM, Greenson JK, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology working group report. Biol Blood Marrow Transplant. 2015;21(4):589–603.CrossRefGoogle Scholar
  3. 3.
    Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.CrossRefGoogle Scholar
  4. 4.
    Bruggen MC, Klein I, Greinix H, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood. 2014;123(2):290–9.CrossRefGoogle Scholar
  5. 5.
    Nishiwaki S, Terakura S, Ito M, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood. 2009;114(14):3113–6.CrossRefGoogle Scholar
  6. 6.
    Terakura S, Martin PJ, Shulman HM, Storer BE. Cutaneous macrophage infiltration in acute GvHD. Bone Marrow Transplant. 2015;50(8):1135–7.CrossRefGoogle Scholar
  7. 7.
    Inamoto Y, Jagasia M, Wood WA, et al. Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplant. 2014;49(4):532–8.CrossRefGoogle Scholar
  8. 8.
    Jacobsohn DA, Montross S, Anders V, Vogelsang GB. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant. 2001;28(11):1047–51.CrossRefGoogle Scholar
  9. 9.
    Hillen U, Hausermann P, Massi D, et al. Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2015;29(5):948–54.CrossRefGoogle Scholar
  10. 10.
    Annette S. H. Gouw, Andrew D. Clouston, Neil D. Theise, (2011) Ductular reactions in human liver: Diversity at the interface. Hepatology 54 (5):1853–63CrossRefGoogle Scholar
  11. 11.
    Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8(3):463–70.CrossRefGoogle Scholar
  12. 12.
    Evans AT, Loeb KR, Shulman HM, et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol. 2015;39(2):212–20.CrossRefGoogle Scholar
  13. 13.
    Cooksley WG, McIvor CA. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacother. 1995;49(3):117–24.CrossRefGoogle Scholar
  14. 14.
    McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544–50.CrossRefGoogle Scholar
  15. 15.
    Castilla-Llorente C, Martin PJ, McDonald GB, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966–71.CrossRefGoogle Scholar
  16. 16.
    Sale G, Shulman H, Hackman RC. Pathology of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 3rd ed. Oxford: Blackwell Publishing Ltd; 2004. p. 286–99.Google Scholar
  17. 17.
    Myerson D, Steinbach G, Gooley TA, Shulman HM. Graft-versus-host disease of the gut: A histologic activity grading system and validation. Biol Blood Marrow Transplant. 2017;23:1573.CrossRefGoogle Scholar
  18. 18.
    Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.CrossRefGoogle Scholar
  19. 19.
    Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–34.CrossRefGoogle Scholar
  20. 20.
    Abu Zaid M, Wu J, Wu C, et al. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017;129(2):162–70.CrossRefGoogle Scholar
  21. 21.
    Paczesny S. Biomarkers for post-transplantation outcomes. Blood. 2018;131:2193.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of PathologyUniversity of Washington School of MedicineSeattleUSA
  3. 3.Pathology SectionSeattle Cancer Care AllianceSeattleUSA

Personalised recommendations